Due to the inconspicuous clinical manifestations in NPDR, current therapies primarily comprise photocoagulation, vitrectomy, and intraocular injection of anti‐vascular endothelial growth factor (anti‐VEGF) or glucocorticoids, with a main focus on the advanced stage of PDR, where treatment effects are often poor [4, 7]. This evidence concerns the gene VEGFA and non-proliferative diabetic retinopathy.